An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension
An Asian, Multicenter, Randomized, Double-blind, Placebo-controlled, 14-week Study of Mirogabalin in Participants With Central Neuropathic Pain Followed by a 52-week, Open-label Extension
Investigate the efficacy and safety of mirogabalin in participants with central neuropathic pain in comparison to placebo
[Double Blind Phase] The primary objective is to compare change in the Average Daily Pain Score (ADPS) from baseline to Week 14 in Asian participants with central neuropathic pain (central neuropathic pain after spinal cord injury) receiving mirogabalin versus placebo.
[Open Extension Phase] The objective is to assess the long-term safety and efficacy of mirogabalin in participants with central neuropathic pain (central neuropathic pain after spinal cord injury, central post stroke pain, and central neuropathic pain in Parkinson's disease).
Inclusion Criteria:
Exclusion Criteria:
Ehime, 790-0024, Japan
Gunma, 371-0811, Japan
Hokkaido, 006-8555, Japan
Hokkaido, 041-8680, Japan
Hokkaido, 060-8543, Japan
Hokkaido, 060-8570, Japan
Hokkaido, 060-8604, Japan
Hokkaido, 070-8530, Japan
Hokkaido, 072-0015, Japan
Kanagawa, 222-0036, Japan
Jeollabuk-do, 54907, South Korea